Background
Methods
Statistical analysis
Results
Patient characteristics
Total (n = 59) | TDT (n = 33) | CMS (n = 26) | p value | |
---|---|---|---|---|
Gender | 0.939 | |||
Male | 40 | 23 | 17 | |
Female | 19 | 10 | 9 | |
Age (range)* | 69 (46–90) | 68 (46–90) | 70 (50–85) | 0.367 |
Diabetes mellitus | 0.180 | |||
Positive | 15 | 11 | 4 | |
Negative | 44 | 22 | 22 | |
Body mass index, kg/m2 (range)* | – | 20.9 (17.0–41.5) | 20.7 (13.2–29.3) | 0.803 |
Chief complaint | – | |||
Abdominal pain/fullness | 34 | 21 | 13 | |
Vomiting | 4 | 3 | 1 | |
Constipation | 5 | 3 | 2 | |
Bloody stool | 7 | 3 | 4 | |
Diarrhea | 1 | 1 | 0 | |
Anemia | 4 | 0 | 4 | |
Others | 4 | 2 | 2 | |
Tumor location | 0.366 | |||
Transverse | 2 | 0 | 2 | |
Descending | 9 | 6 | 3 | |
Sigmoid | 38 | 21 | 17 | |
Rectosigmoid | 10 | 6 | 4 | |
Dilatation of the small bowel | ||||
Positive | 27 | 16 | 11 | 0.749 |
Negative | 32 | 17 | 15 | |
Maximum of dilatation of the colon, mm (range)* | – | 59.9 (33.0–95.3) | 48.8 (29.2–76.8) | 0.099 |
CEA, ng/ml (range)* | 10.0 (2.9–490.8) | 6.6 (1.0–1232.0) | 0.242 | |
TDT | 33 | – | – | |
CMS | 26 | – | – | |
Stage | 0.441 | |||
II | 22 | 11 | 11 | |
III | 17 | 11 | 6 | |
IV | 20 | 11 | 9 |
Clinical outcomes
TDT group (n = 33) | CMS group (n = 26) | p value | |
---|---|---|---|
Clinical success (%) | 27 (81.8) | 26 (100) | 0.03 |
Clinical failure (%) | 6 (18.2) | 0 | |
Perforation | 3 (9.1) | 0 | |
Migration | 2 (6.1) | 0 | |
Inadequate decompression | 1 (3.0) | 0 | |
Solid food intake | < 0.01 | ||
Resumed | 0 | 26 | |
Not resumed | 33 | 0 | |
Temporary discharge | < 0.01 | ||
Yes | 0 | 26 | |
No | 33 | 0 | |
Duration of tube placement, days (range)* | 17 (6–54) | 9 (1–30) | < 0.01 |
TDT group (n = 33) | CMS group (n = 26) | p value | |
---|---|---|---|
Surgical approach | < 0.01 | ||
Laparoscopic (%) | 0 | 20 (76.9) | |
Open (%) | 33 (100) | 6 (23.1) | |
Surgical procedure | |||
Partial resection | 1 | 0 | – |
Left hemicolectomy | 4 | 3 | |
Sigmoidectomy | 8 | 1 | |
Hartmann procedure | 7 | 6 | |
Anterior resection | 13 | 16 | |
Operative time, minutes (range)* | 205 (100–447) | 367 (210–597) | < 0.01 |
Blood loss, g (range)* | 205 (0–1275) | 102 (0–1492) | 0.369 |
Stoma creation during primary operation (%) | 12 (36.4) | 8 (30.8) | 0.862 |
Postoperative complications (%) (the Clavien-Dindo classification) | 0.151 | ||
Grade 0 | 24 (72.7) | 16 (61.5) | |
1 | 4 (12.1) | 1 (3.9) | |
2 | 4 (12.1) | 7 (26.9) | |
3 | 1 (3.1) | 2 (7.7) | |
4 | 0 (0) | 0 (0) | |
Surgical site infection (%) | 0.685 | ||
Positive | 4 (12.1) | 2 (7.7) | |
Negative | 29 (78.9) | 24 (92.3) | |
Hospital stay, days (range)* | 28 (14–75) | 27.5 (12–114) | 0.502 |
Stoma reversal (%) | 2 (6.1) | 2 (7.7) | |
Permanent stoma creation (%) | 10 (30.3) | 6 (23.1) | 0.745 |
Clinicopathological outcomes
TDT group (n = 33) | CMS group (n = 26) | p value | |
---|---|---|---|
Tumor size, cm (range)* | 4.5 (3.0–9.0) | 5.5 (3.5–11.0) | 0.008 |
Histological type (%) | 0.470 | ||
Tub 1 | 11 (33.3) | 7 (26.9) | |
Tub 2 | 20 (60.7) | 16 (61.6) | |
Por | 1 (3.0) | 1 (3.8) | |
Muc | 0 (0) | 2 (7.7) | |
Sci | 1 (3.0) | 0 (0) | |
Stage (%) | 0.441 | ||
II | 11 (33.3) | 11 (42.3) | |
III | 11 (33.3) | 6 (23.1) | |
IV | 11 (33.3) | 9 (34.6) | |
Lymph nodes, n (range)* | 9 (1–23) | 19 (6–40) | < 0.01 |
Resection status (%) | < 0.01 | ||
D1 | 3 (9.1) | 0 (0) | |
D2 | 12 (36.4) | 1 (3.8) | |
D3 | 18 (54.5) | 25 (96.2) | |
Recurrence (%) | 0.424 | ||
Yes | 9 (40.9) | 4 (23.5) | |
No | 13 (59.1) | 13 (76.5) | |
Observation period, days (range)* | 1516 (17–4773) | 608 (52–1601) |
TDT group (n = 33) | CMS group (n = 26) | |
---|---|---|
Adjuvant therapy | ||
Stage II | ||
Negative | 7 | 6 |
Oral 5FU/leucovorin or oral 5FU | 3 | 2 |
Capecitabine + oxaliplatin | 0 | 3 |
mFOLFOX6 | 1 | 0 |
Stage III | ||
Negative | 2 | 2 |
Oral 5FU/leucovorin or oral 5FU | 7 | 1 |
Capecitabine + oxaliplatin ∓ bevacizumab | 1 | 2 |
unknown | 1 | 1 |
Stage IV | ||
Best supportive care | 3 | 2 |
Oral 5FU/leucovorin or oral 5FU | 1 | 2 |
mFOLFOX6 ∓ bevacizumab | 3 | 2 |
mFOLFOX6 + panitumumab | 0 | 1 |
Capecitabine + oxaliplatin ∓ bevacizumab | 1 | 2 |
S1 + oxaliplatin + bevacizumab | 1 | 0 |
Others | 2 | 0 |